Skip to main content
PMC home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Jul 10;12(1):77–90. doi: 10.1111/j.1527-3458.2006.00077.x

Neuroprotective Activity of 3‐Aminopyridine‐2‐Carboxaldehyde Thiosemicarbazone (PAN‐811), a Cancer Therapeutic Agent

Zhi‐Gang Jiang 1,✉, Michael S Lebowitz 1, Hossein A Ghanbari 1
PMCID: PMC6741723  PMID: 16834759

Abstract

3‐aminopyridine‐2‐carboxaldehyde thiosemicarbazone (3‐AP) is a highly‐hydrophobic small molecule that was originally developed for cancer therapy (Triapine®, Vion Pharmaceuticals) due to its ability to inhibit ribonucleotide reductase, a key enzyme required for DNA synthesis. 3‐AP has a high affinity for divalent cations, chelating the Fe2+ at the R2 subunit of the enzyme and inhibiting formation of a tyrosyl radical essential for ribonucleotide reduction. We have demonstrated that 3‐AP is also a potent neuroprotectant (as such, it is referred to as “PAN‐811”). In vitro it completely blocks ischemic neurotoxicity at a concentration of 0.5 μM (EC50 ≊ 0.35 μM) and hypoxic toxicity at 1.2 μM (EC50 ≊ 0.75 μM). Full protection of primary cortical and striatal neurons can be achieved with 3‐AP when it is added to the medium at up to six hours after an ischemic insult. 3‐AP also suppresses cell death induced by neurotoxic agents, including staurosporine, veratridine and glutamate, indicating activity against a central target(s) in the neurodegenerative process. 3‐AP acts via neutralization of two important intracellular effectors of excitatory neurotoxicity; calcium and free radicals. Its reported ability to elevate anti‐apoptotic proteins is likely to be a consequence of the suppression of excessive intracellular free calcium. In a rat model of transient ischemia, a single bolus delivery of 3‐AP 1 h after the initiation of ischemic attack reduced infarct volume by 59% when administered i.c.v. (50 μg per rat) and by 35% when administered i.v. (1 mg/kg). In Phase I clinical trials in cancer therapy 3‐AP had no cardiovascular, CNS or other major adverse effects. Thus, 3‐AP has a high potential for development as a novel, potent neuroprotectant for the treatment of neurodegenerative diseases.

Keywords: 3‐AP, Brain ischemia, Free radical scavengers, Metal chelators, Neuro‐protection, PAN‐811, Stroke, Triapine®

Full Text

The Full Text of this article is available as a PDF (175.8 KB).

REFERENCES

  • 1. Abeysinghe RD, Greene BT, Haynes R, et al. p53‐Independent apoptosis mediated by tachpyridine, an anticancer iron chelator. Carcinogenesis 2001;22: 1607–1614. [DOI] [PubMed] [Google Scholar]
  • 2. Bastianetto S, Ramassamy C, Dore S, Christen Y, Poirier J, Quirion R. The Ginkgo biloba extract (EGB761) protects hippocampal neurons against cell death induced by β‐amyloid. Eur J Neurosci 2000;12: 1882–1890. [DOI] [PubMed] [Google Scholar]
  • 3. Beckloff GL, Lerner HJ, Frost D, Russo‐Alesi FM, Gitomer S. Hydroxyurea (NSC‐32065) in biological fluids: Dose‐concentration relationship. Cancer Chemother Rep 1965;48: 57–58. [PubMed] [Google Scholar]
  • 4. Bonisch H, Graefe KH, Keller B. Tetrodotoxin‐sensitive and ‐resistant effects of veratridine on the noradrenergic neurone of the rat vas deferens. Naunyn Schmiedeberg's Arch Pharmacol 1983;324: 264–270. [DOI] [PubMed] [Google Scholar]
  • 5. Booth BA, Donnelly TE Jr, Zettner A, Sartorelli AC. Metabolic effects of zinc in intact cells — comparative studies of zinc chloride and the zinc chelate of kethoxal bis(thiosemicarbazone). Biochem Pharmacol 1971;20: 3109–3118. [DOI] [PubMed] [Google Scholar]
  • 6. Booth BA, Sartorelli AC. Synergistic interaction of kethoxal bis(thiosemicarbazone) and cupric ions in sarcoma 180. Nature 1966;210: 104–105. [DOI] [PubMed] [Google Scholar]
  • 7. Callaway JK, Beart PM, Jarrott B, Giardina SF. Incorporation of sodium channel blocking and free radical scavenging activities into a single drug, AM‐36, results in profound inhibition of neuronal apoptosis. Br J Pharmacol 2001;132: 1691–1698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Chaston TB, Lovejoy DB, Watts RN, Richardson DR. Examination of the antiproliferative activity of iron chelators: Multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin Cancer Res 2003;9: 402–414. [PubMed] [Google Scholar]
  • 9. Chen R‐W, Yao C, Lu XCM, et al. PAN‐811, a novel neuroprotectant elicits its function in primary neuronal cultures by up‐regulating Bcl‐2 expression. Neuroscience 135: 191–201, 2005. [DOI] [PubMed] [Google Scholar]
  • 10. Conte V, Uryu K, Fujimoto S, et al. Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. J Neurochem 2004;90: 758–764. [DOI] [PubMed] [Google Scholar]
  • 11. Cory JG, Cory AH, Rappa G, et al. Inhibitors of ribonucleotide reductase. Comparative effects of amino‐ and hydroxy‐substituted pyridine‐2‐carboxaldehyde thiosemicarbazones. Biochem Pharmacol 1994;48: 335–344. [DOI] [PubMed] [Google Scholar]
  • 12. Cory JG, Sato A. Regulation of ribonucleotide reductase activity in mammalian cells. Mol Cell Biochem 1983;53: 257–266. [DOI] [PubMed] [Google Scholar]
  • 13. Creasey WA, Agrawal KC, Capizzi RL, Stinson KK, Sartorelli AC. Studies of the antineoplastic activity and metabolism of α‐(N)‐heterocyclic carboxaldehyde thiosemicarbazones in dogs and mice. Cancer Res 1972;32: 565–572. [PubMed] [Google Scholar]
  • 14. Darnell G, Richardson DR. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: The effect of the ligands on molecular targets involved in proliferation. Blood 1999;94: 781–792. [PubMed] [Google Scholar]
  • 15. Feun L, Modiano M, Lee K, et al. Phase I and pharmacokinetic study of 3‐aminopyridine‐2‐carboxaldehyde thiosemicarbazone (3‐AP) using a single intravenous dose schedule. Cancer Chemother Pharmacol 2002;50: 223–229. [DOI] [PubMed] [Google Scholar]
  • 16. Finch RA, Liu M, Grill SP, et al. Triapine (3—aminopyridine‐2‐carboxaldehyde‐thiosemicarbazone): Apotent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem Pharmacol 2000;59: 983–991. [DOI] [PubMed] [Google Scholar]
  • 17. Finch RA, Liu MC, Cory AH, Cory JG, Sartorelli AC. Triapine (3‐aminopyridine‐2‐carboxaldehyde thiosemicarbazone; 3‐AP): An inhibitor of ribonucleotide reductase with antineoplastic activity. Adv Enzyme Regul 1999;39: 3–12. [DOI] [PubMed] [Google Scholar]
  • 18. Folbergrova J, Zhao Q, Katsura K, Siesjo BK. N‐tert‐butyl‐α‐phenylnitrone improves recovery of brain energy state in rats following transient focal ischemia. Proc Natl Acad Sci USA 1995;92: 5057–5061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Gao J, Richardson DR. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell‐cycle progression. Blood 2001;98: 842–850. [DOI] [PubMed] [Google Scholar]
  • 20. Ghanbari HA, Ghanbari KG, Harris PLR, et al. Oxidative damage in cultured human olfactory neurons from Alzheimer's disease patients. Aging Cell 2004;3: 41–44. [DOI] [PubMed] [Google Scholar]
  • 21. Gil J, Almeida S, Oliveira CR, Rego AC. Cytosolic and mitochondrial ROS in staurosporine‐induced retinal cell apoptosis. Free Radic Biol Med 2003;35: 1500–1514. [DOI] [PubMed] [Google Scholar]
  • 22. Giles FJ, Fracasso PM, Kantarjian HM, et al. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res 2003;27: 1077–1083. [DOI] [PubMed] [Google Scholar]
  • 23. Gwilt PR, Tracewell WG. Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin Pharmacokinet 1998;34: 347–358. [DOI] [PubMed] [Google Scholar]
  • 24. Honda K, Casadesus G, Petersen RB, Perry G, Smith MA. Oxidative stress and redox‐active iron in Alzheimer's disease. Ann NY Acad Sci 2004;1012: 179–182. [DOI] [PubMed] [Google Scholar]
  • 25. Jiang Z‐G, Nelson V, Pan W, et al. Neurodegeneration caused by hypoxia and ischemia do not share the same mechanism of action. Society for Neuroscience; 33d Annual Meeting, New Orleans , 2003. Program Number: 446.10. [Google Scholar]
  • 26. Jiang Z‐G, Nelson V, Almassian B, Ghanbari H. PAN‐811: A multifunctional neuroprotectant. Society for Neuroscience; 34th Annual Meeting, San Diego , 2004. Program Number 101–10. [Google Scholar]
  • 27. Jiang Z‐G, Almassian B, Nelson V, Ghanbari H. A neuroprotectant, PAN‐811, representing a novel neuroprotective approach to treat neurodegenerative diseases. The 9th International Conference on Alzheimer's Disease and Related Disorders, Philadelphia , 2004. Control Number: 04‐A‐1491‐ALZ. [Google Scholar]
  • 28. Jiang Z‐G, Lu X‐C M, Nelson V, et al. A multi‐functional cytoprotective agent that can reduce stroke‐induced neurodegeneration when administered even after ischemic attack. Proc Natl Acad Sci USA 2006;103: 1581–1586. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Jordan J, Galindo MF, Calvo S, Gonzalez‐Garcia C, Cena V. Veratridine induces apoptotic death in bovine chromaffin cells through superoxide production. Br J Pharmacol 2000;130: 496–1504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Jordan J, Galindo MF, Tornero D, et al. Superoxide anions mediate veratridine‐induced cytochrome c release andcaspase activity in bovine chromaffin cells. Br J Pharmacol 2002;137: 993–1000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Kolberg M, Strand KR, Graff P, Andersson KK. Structure, function, and mechanism of ribonucleotide reduc‐tases. Biochim Biophys Acta 2004;1699: 1–34. [DOI] [PubMed] [Google Scholar]
  • 32. DeConti RC, Toftness BR, Agrawal KC, et al. Clinical and pharmacological studies with 5‐hydroxy‐2‐formylpyridine thiosemicarbazone. Cancer Res 1972;32: 1455–1462. [PubMed] [Google Scholar]
  • 33. Kristian T, Gido G, Kuroda S, Schutz A, Siesjo BK. Calcium metabolism of focal and penumbral tissues in rats subjected to transient middle cerebral artery occlusion. Exp Brain Res 1998;120: 503–509. [DOI] [PubMed] [Google Scholar]
  • 34. Kruman II, Mattson MP. Pivotal role of mitochondrial calcium uptake in neural cell apoptosis and necrosis. J Neurochem 1999;72: 529–540. [DOI] [PubMed] [Google Scholar]
  • 35. Lee IK, Yun BS, Kim JP, et al. p‐Terphenyl curtisians protect cultured neuronal cells against glutamate neurotoxicity via iron chelation. Planta Med 2003;69: 513–517. [DOI] [PubMed] [Google Scholar]
  • 36. Linnik MD, Miller JA, Sprinkle‐Cavallo J, et al. Apoptotic DNA fragmentation in the rat cerebral cortex induced by permanent middle cerebral artery occlusion. Brain Res Mol Brain Res 1995;32: 116–124. [DOI] [PubMed] [Google Scholar]
  • 37. Liu MC, Lin TS, Sartorelli AC. Synthesis and antitumor evaluation of amino derivatives of pyridine‐2‐carboxaldehyde thiosemicarbazone. J Med Chem 1992;3672–3677. [DOI] [PubMed] [Google Scholar]
  • 38. Liu S, Liu M, Peterson S, Miyake M, Vallyathan V, Liu KJ. Hydroxyl radical formation is greater in striatal core than in penumbra in a rat model of ischemic stroke. J Neurosci Res 2003;71: 882–888. [DOI] [PubMed] [Google Scholar]
  • 39. Liu S, Shi H, Liu W, Furuichi T, Timmins GS, Liu KJ. Interstitial pO2 in ischemic penumbra and core are differentially affected following transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab 2004;24: 343–349. [DOI] [PubMed] [Google Scholar]
  • 40. Lovejoy DB, Richardson DR. Novel “hybrid” iron chelators derived from aroylhydrazones and thiosemicar‐bazones demonstrate selective antiproliferative activity against tumor cells. Blood 2002;100: 666–676. [DOI] [PubMed] [Google Scholar]
  • 41. Lu X‐C M, Yang X, Chen RW, et al. A novel neuroprotectan, Pan‐811, decreases infarct volume following transient focal cerebral ischemia in rats. Society for Neuroscience; 34th Annual Meeting, San Diego , 2004. San Diego, CA. Program Number 343–3. [Google Scholar]
  • 42. Luetjens CM, Bui NT, Sengpiel B, et al. Delayed mitochondrial dysfunction in excitotoxic neuron death: Cytochrome c release and a secondary increase in superoxide production. J Neurosci 2000;20: 5715–5723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Moore EC, Sartorelli AC. The inhibition of ribonucleotide reductase by α‐(N)‐heterocyclic carboxaldehyde thiosemicarbazones In: Cory JG, Cory AH, Eds. Inhibitors of ribonucleoside diphosphate reductase activity. Oxford : Pergamon Press, 1989;203–215. [Google Scholar]
  • 44. Moore EC, Hurlert RB. The inhibition of ribonucleoside diphosphate reductase by hydroxyurea, guanazole and pyrazoloimidazole (IMPY) In: Cory JG, Cory AH, Eds. Inhibitors of ribonucleoside diphosphate reductase activity. Oxford : Pergamon Press, 1989;165–201. [Google Scholar]
  • 45. Murren J, Modiano M, Clairmont C, et al. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Clin Cancer Res 2003;9: 4092–4100. [PubMed] [Google Scholar]
  • 46. Neumar RW, Xu YA, Gada H, Guttmann RP, Siman R. Cross‐talk between calpain and caspase proteolytic systems during neuronal apoptosis. J Biol Chem 2003;278: 14162–14167. [DOI] [PubMed] [Google Scholar]
  • 47. Onteniente B, Couriaud C, Braudeau J, Benchoua A, Guegan C. The mechanisms of cell death in focal cerebral ischemia highlight neuroprotective perspectives by anti‐caspase therapy. Biochem Pharmacol 2003;66: 1643–1649. [DOI] [PubMed] [Google Scholar]
  • 48. Pike BR, Zhao X, Newcomb JK, Wang KK, Posmantur RM, Hayes RL. Temporal relationships between de novo protein synthesis, calpain and caspase 3‐like protease activation, and DNA fragmentation during apoptosis in septohippocampal cultures. J Neurosci Res 1998;52: 505–520. [DOI] [PubMed] [Google Scholar]
  • 49. Reichard P. The anaerobic ribonucleotide reductase from Escherichia coli. J Biol Chem 1993;268: 8383–8386. [PubMed] [Google Scholar]
  • 50. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate‐to‐severe Alzheimer's disease. N Engl J Med 2003;348: 1333–1341. [DOI] [PubMed] [Google Scholar]
  • 51. Richardson DR, Tran EH, Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 1995;86: 4295–4306. [PubMed] [Google Scholar]
  • 52. Richardson DR, Milnes K. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: The mechanism of action of ligands derived from salicylaldehyde ben‐zoyl hydrazone and 2‐hydroxy‐1‐naphthylaldehyde benzoyl hydrazone. Blood 1997;89: 3025–3038. [PubMed] [Google Scholar]
  • 53. Sartorelli AC, Agrawal KC, Moore EC. Mechanism of inhibition of ribonucleoside diphosphate reductase by α‐(N)‐heterocyclic aldehyde thiosemicarbazones. Biochem Pharmacol 1971;20: 3119–3123. [DOI] [PubMed] [Google Scholar]
  • 54. Stubbe J. Ribonucleotide reductases: Amazing and confusing. J Biol Chem 1990;265: 5329–5332. [PubMed] [Google Scholar]
  • 55. Takeda E, Weber G Role of ribonucleotide reductase in expression in the neoplastic program. Life Sci 1981;28: 1007–1014. [DOI] [PubMed] [Google Scholar]
  • 56. Tam TF, Leung‐Toung R, Li W, Wang Y, Karimian K, Spino M. Iron chelator research: past, present, and future. Curr Med Chem 2003;10: 983–995. [DOI] [PubMed] [Google Scholar]
  • 57. Thelander L, Graslund A. Mechanism of inhibition of mammalian ribonucleotide reductase by the iron chelate of 1‐formylisoquinoline thiosemicarbazone. Destruction of the tyrosine free radical of the enzyme in an oxygen‐requiring reaction. J Biol Chem 1983;258: 4063–4066. [PubMed] [Google Scholar]
  • 58. Thelander L, Graslund A, Thelander M. Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: Possible regulation mechanism. Biochem Biophys Res Commun 1983;110: 859–865. [DOI] [PubMed] [Google Scholar]
  • 59. Thelander M, Graslund A, Thelander L. Subunit M2 of mammalian ribonucleotide reductase. Characterization of a homogeneous protein isolated from M2—overproducing mouse cells. J Biol Chem 1985;260: 2737–2741. [PubMed] [Google Scholar]
  • 60. Thelander L, Reichard P. Reduction of ribonucleotides. Annu Rev Biochem 1979;48: 133–158. [DOI] [PubMed] [Google Scholar]
  • 61. Torti SV, Torti FM, Whitman SP, Brechbiel MW, Park G, Planalp RP. Tumor cell cytotoxicity of a novel metal chelator. Blood 1998;92: 1384–1389. [PubMed] [Google Scholar]
  • 62. Wadler S, Makower D, Clairmont C, Lambert P, Fehn K, Sznol M. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3‐aminopyridine‐2‐carboxaldehyde thiosemicarbazone, administered by 96‐h intravenous continuous infusion. J Clin Oncol 2004;22: 1553–1563. [DOI] [PubMed] [Google Scholar]
  • 63. Weller M, Marini AM, Finiels‐Marlier F, Martin B, Paul SM. MK‐801 and memantine protect cultured neurons from glutamate toxicity induced by glutamate carboxypeptidase‐mediated cleavage of methotrexate. Eur J Pharmacol 1993;248: 303–312. [DOI] [PubMed] [Google Scholar]
  • 64. Wenk GL, Danysz W, Mobley SL. MK‐801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur J Pharmacol 1995;293: 267–270. [DOI] [PubMed] [Google Scholar]
  • 65. Witt L, Yap T, Blakley RL. Regulation of ribonucleotide reductase activity and its possible exploitation in chemotherapy. Adv Enzyme Regul 1978; 157–171. [DOI] [PubMed] [Google Scholar]
  • 66. Zipfel GJ, Babcock DJ, Lee JM, Choi DW. Neuronal apoptosis after CNS injury: The roles of glutamate and calcium. J Neurotrauma 2000;17: 857–869. [DOI] [PubMed] [Google Scholar]
  • 67. Zhuang H, Pin S, Christen Y, Dore S. Induction of heme oxygenase 1 by Ginkgo biloba in neuronal cultures and potential implications in ischemia. Cell Mol Biol 2002;48: 647–653. [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES